MedTrace Logo

The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure

NCT00613964 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2011-07-22

No results posted yet for this study

Summary

Carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in patients with heart failure through a vasodilatory action, a natriuretic action, and inhibition of the renin-angiotensin-aldosterone system and has been widely-used in Japan. However, a paucity of report is available on the effects of carperitide on short and long-term prognosis in patients with both cardiac and renal failure. The purpose of this study is to evaluate the effects of carperitide therapy on short and long-term prognosis in patients with both cardiac and renal failure, in comparison with standard therapy.

Conditions

Interventions

DRUG

Carperitide heart failure therapy

carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)

DRUG

Standard heart failure therapy

Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis

Sponsors & Collaborators

  • Nara Medical University

    lead OTHER

Principal Investigators

  • Yoshihiko Saito, MD, PhD · First Department of Internal Medicine, Nara Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00613964 on ClinicalTrials.gov